Imaging Endpoint (IE) is a global leader in imaging CRO technology and services for oncology testing and has announced the filing of a provisional patent application for its innovative AI-enhanced Imaging Review Charter (IRC) system. This innovative Airc System™ is designed to enhance highly customized IRC for clinical trials, setting new standards in the industry.
Imaging endpoints are the scientific leader in customizing and optimizing image acquisition and optimization for clinical trials in oncology, and are the industry's most sophisticated approach to ensuring clarification and/or modification of published criteria to enhance each unique clinical trial design. This sophisticated approach to image analysis contributes to the company's outstanding 95% marketing approval success rate, which supports over 200 regulatory approvals.
The new AIRC system addresses longstanding challenges in testing imaging design by ensuring the alignment of current regulatory requirements of FDAs, EMAs and other regulatory bodies around the world, while helping Intelligent, Taulared Modification and/or Clarification assimilate data to standard oncology standards.
Also Read: Aithority Interview with Speakup CEO Tim Morrs
Key features of the new AIRC system:
- Dynamic Customization: The system includes customization modules that integrate industry standards, published oncology standards, imaging endpoint customizations for analytical customizations of imaging endpoints, and trial information from experimental agents (such as mechanisms of action) to generate dynamic IRC documents.
- Optimizing Criteria: The system provides the largest dataset and key methods for identifying the specific criteria needed to optimize image acquisition and analysis for each unique trial.
- Enhanced Regulatory Compliance: Globally integrating FDA and other regulatory agencies' requirements, standards, guidelines, and recent industry-wide findings help to better explain standards strengthening, while the AIRC system helps optimize compliance with regulatory standards while improving efficiency in sponsor and agency reviews.
- Increased efficiency: The system utilizes AI to compile and integrate data applied to IE physicians, science, operations and regulatory experts.
Doug Dean BurkettThe CEO and president of Imaging Endpoint commented on the innovation: “For over 15 years, IE has been at the forefront of intratumoral imaging CRO services. The submission of this patent illustrates another milestone in its commitment to strengthening imaging to enhance the effectiveness of strengthening IRC systems that enhance imaging and further strengthen our industry leadership.
